TABLE 1

Subject demographics and study characteristicsa

Demographic group or characteristicMean no. (%) of subjects
All groupsMenACWY only, Grp 1MenACWY Plus Tdap only, Grp 2MenACWY Plus 4 not Tdap/IPV, Grp 3MenACWY Plus 4 not Tdap, Grp 4
Total no. of subjects3204124105150
Sex
    Female80 (25)9 (22)7 (29)13 (12)51 (34)
    Male240 (75)32 (78)17 (71)92 (88)99 (66)
Race/ethnicity
    White214 (67)31 (76)18 (75)74 (70)91 (61)
    Black56 (17)4 (10)1 (4)14 (13)37 (25)
    Hispanic27 (9)2 (5)0 (0)12 (11)13 (9)
    Asian10 (3)1 (2)2 (8)2 (2)5 (3)
    NS13 (4)3 (7)3 (13)3 (3)3 (2)
Age group (yr; range, 17 to 43)
    17–20166 (52)15 (37)3 (13)72 (69)76 (51)
    21–25111 (35)17 (41)7 (29)30 (29)57 (38)
    ≥2643 (13)9 (25)14 (58)3 (3)17 (11)
    Mean (yr)21.623.425.820.021.5
Months postvaccination
    Mean4.964.63.545.444.95
    Range1–121–121–81–91–11
  • a NS, race/ethnicity was either “not specified,” “other,” or Native American; there were too few cases of each for analysis; Grp, group; IPV, inactivated polio vaccine; MenACWY, tetravalent meningococcal conjugate vaccine A, C, W, and Y; Tdap, tetanus-diphtheria-acellular pertussis vaccine.